Traws Pharma (NASDAQ:TRAW) Trading Down 18.5% – Should You Sell?

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) fell 18.5% during mid-day trading on Tuesday . The company traded as low as $4.66 and last traded at $5.06. 125,255 shares were traded during mid-day trading, an increase of 18% from the average session volume of 106,066 shares. The stock had previously closed at $6.21.

Traws Pharma Price Performance

The company has a 50-day simple moving average of $7.43.

Institutional Investors Weigh In On Traws Pharma

A number of large investors have recently added to or reduced their stakes in the company. Alyeska Investment Group L.P. purchased a new stake in Traws Pharma during the fourth quarter valued at about $1,036,000. Vestal Point Capital LP purchased a new stake in Traws Pharma during the fourth quarter valued at about $666,000. Boothbay Fund Management LLC purchased a new stake in Traws Pharma during the fourth quarter valued at about $252,000. Geode Capital Management LLC purchased a new stake in Traws Pharma during the fourth quarter valued at about $185,000. Finally, Renaissance Technologies LLC purchased a new stake in Traws Pharma during the fourth quarter valued at about $89,000. Hedge funds and other institutional investors own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.